Can the new FDA-approved weight loss drug Wegovy (semaglutide) be used in a patient that had gastric bypass surgery years previously?
Yes, Wegovy®, an FDA-approved weight loss medication, can be used in patients who have had gastric bypass surgery as well as other bariatric surgical procedures including, but not limited to, lap-band and gastric sleeve. Wegovy (semaglutide) is in the class of medications called GLP-1 receptor agonists which also includes Saxenda® and Ozempic®. A study found that this class of medication was more effective for weight loss in patients who have had bariatric surgery than non-GLP-1 receptor agonist medications such as phentermine, Qsymia® and Contrave®. A different study looking at patients who have had bariatric surgery in the past and were treated with semaglutide (up to 0.5 mg), demonstrated on average ~10% total body weight loss after 6 months.
Learn more about how FORM doctors prescribe Wegovy to help patients achieve their weight loss goals.
Wegovy® is a registered trademark of Novo Nordisk A/S.
Lauren Lemieux, MD
FACP, ABOM diplomate
Dr. Lauren Lemieux completed her Internal Medicine residency and fellowship in Clinical Nutrition at UCLA. She is board certified in Internal Medicine and diplomate of the American Board of Obesity Medicine, and as a Physician Nutrition Specialist. She is also a fellow of the American College of Physicians. Dr. Lemieux is passionate about helping her patients reach their health goals using personalized nutrition, lifestyle and weight management strategies.
